BRCA2 and ovarian carcinoma: A recent review pointed out the predominance of deleterious variants in breast and ovarian cancer genes among PanC patients, with BRCA2 and ATM having the highest prevalence of pathogenic mutations in both sporadic and unselected PanC (Astiazaran-Symonds and Goldstein 2021).